Targeted delivery of anti-Her2-β-1,3-(D)-Glucan-doxorubicin conjugated nanoparticles as an antigen specific therapy of breast cancer

Nowadays nanomedicine is emerging as a great concern in cancerous patients isincreasing because of the side effects of most anticancer agents. Antibodyconjugatednanoparticles (Ab-NPs) have been a remarkable choice to overcomethese limitations in therapeutics. This survey aims to determine the specificity,sensitivity and accuracy of her2 positive receptor monoclonal antibody,trastuzumab (Herceptin), with modified nanoparticulated (trastuzumab mAb-β-1,3-(D)-Glucan-Doxorubicin ) delivery system to her2 positive breast cancercells. In this study, β-1,3-(D)-Glucan, as a new nanocarrier, was prepared fromcell wall of Candida albicans, normal flora in human. Glucan was modified toN-succynated form for conjugation ofpolyethyleneimine (PEI) as a known internalization enhancer. Then thenanoparticle containing anti cancer agent was formulated by self-assemblymethod using β-1,3-(D)-Glucan-PEI and Doxorubicin . For specific targeting ofnanoparticles trastuzumab mAb was directly conjugated to the surface of NPsby oxidation method using sodium periodate (NaIO4). Using dynamic lightscattering (DLS) and zeta potential, nanoparticles was positive in charge anddetermined to be averagely 159 nm in size. Also conjugation of antibody did notsignificantly alter the size of the NPs. Besides, the uniformity and morphologyof the nanospheres was investigated by Scanning electron microscopy (SEM).Biological in-vitro studies showed that the antibody-conjugated nanoparticleswere differentiating between Her2+ and Her2-cells, and seem to have thepotential to be used in active targeted drug delivery, with reduction of drug sideeffects in Her2+breast cancer.